Hot Selling High Purity Pharmaceutical Ranitidine Powder 66357-35-5 with Good Price Ratic
TDS 2 Inquiries
66357-35-5
Pharmaceutical Grade
99%
Shanghai
HNB
1kg/bag, 25kg/drum or as request
2026-05-10
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
Ranitidine
Other Name:1,1-Ethenediamine,N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-;N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine;Ranitidine;Midaven;Zenetac;Ulcerit;Label;70956-04-6;80020-48-0;86386-78-9
CAS No.:66357-35-5
Molecular Formula:C13H22N4O3S
InChIKeys:InChIKey=VMXUWOKSQNHOCA-UHFFFAOYSA-N
Molecular Weight:314.4
Exact Mass:314.40
EC Number:266-332-5
UNII:884KT10YB7
NCI Thesaurus Code:C29412
ATC Code:A02BA02
HScode:2932999099
Categories:
Characteristics-
PSA:
112
XLogP3:1.93
Appearance:tan solid
Density:1.184±0.06 g/cm3(Predicted)
Melting Point:69-70 °C
Boiling Point:437.1ºC at 760 mmHg
Refractive Index:1.558
Water Solubility:H2O: 24.7 mg/mL
Storage Conditions:Desiccate at +4°C
Toxicity:LD50 oral in rat: > 5gm/kg
Odor:Characteristic
Taste:Bitter taste
Dissociation Constants:8.2 and 2.7
Hazard IdentificationClassification of the substance or mixture
Skin irritation, Category 2
Skin sensitization, Category 1
Eye irritation, Category 2
Respiratory sensitization, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H315 Causes skin irritation
H317 May cause an allergic skin reaction
H319 Causes serious eye irritation
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P272 Contaminated work clothing should not be allowed out of the workplace.
P284 [In case of inadequate ventilation] wear respiratory protection.
Response P302+P352 IF ON SKIN: Wash with plenty of water/...
P321 Specific treatment (see ... on this label).
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P333+P317 If skin irritation or rash occurs: Get medical help.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P342+P316 If experiencing respiratory symptoms: Get emergency medical help immediately.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Ranitidine hydrochloride tablets or soln should be stored in a dry place @ 15-30 deg C in tight, light-resistant containers. The oral soln should be stored in a tight, light-resistant container @ 4-25 deg C. Ranitidine hydrochloride injection and the commercially available injection of the drug in 0.45% sodium chloride should be protected from light and stored @ 4-30 deg C; however, it is preferable that the latter preparation be stored @ room temp (25 deg C), although brief exposure to temp up to 40 deg C will not adversely affect stability, and that freezing be avoided. Slight darkening of the injection will not affect potency. Ranitidine hydrochloride
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Location:
6 floor Baoyilongji Building B Weiyang Area, Fengcheng 8 Road, Xi'an city, Shaanxi, 710000, China
-
Payment Terms:
L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2017
-
Certifications:
ISO,ISO
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
India
Ranitidine
1 KG Aug 12, 2025
India
Ranitidine
50 MT Apr 21, 2025 Post an enquiry for this product
